Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 140 record(s)

Req # A-2020-001895

Adverse Reaction Reports (AERs) for Mezavant. Report numbers: E2B_03321791, 919523, 924749, E2B_03284156, E2B_03286468, E2B_03292641, E2B_03302640. (ADRs) for Vyvanse. Report numbers: E2B_03300503, E2B_03287086, E2B_03284951. (ADR) for C1 Esterase Inhibitor (Human). Report number: E2B_03287283. (ADRs) for Immunoglobulin (human). Report numbers: E2B_03320951, E2B_03299907, E2B_03286704.

Organization: Health Canada

193 page(s)
July 2021

Req # A-2020-001911

Adverse Reaction Reports (AERs). Report numbers: E2B_02759974, E2B_02760024, E2B_02760057, 000913680, 000908903, E2B_03478100, E2B_03486669, E2B_03486667, 000727436, 000727650, E2B_02718570, E2B_02741388, E2B_02854189, 000732554, 000732551, E2B_02854253, E2B_02866264, E2B_02973462, 000909382, 000913785.

Organization: Health Canada

333 page(s)
July 2021

Req # A-2020-001923

Adverse Reaction Reports (AERs) for Abilify. Report numbers: E2B_03357016, E2B_03433811, E2B_03438670, E2B_03445919, E2B_03448513, E2B_03451979, E2B_03452092, E2B_03452152, E2B_03452156, E2B_03452168, E2B_03452227, E2B_03452236, E2B_03452237, E2B_03452256, E2B_03452263.

Organization: Health Canada

177 page(s)
July 2021

Req # A-2020-001925

Adverse Reaction Reports (AERs) for Abilify. Report numbers: E2B_03459686, E2B_03419120, E2B_03443807, E2B_03448503, E2B_03448516, E2B_03452162, E2B_03452163, E2B_03452350, E2B_03452353, E2B_03452602, E2B_03459110.

Organization: Health Canada

240 page(s)
July 2021

Req # A-2020-001938

Adverse Reaction Reports (AERs) for Dexilant. Report numbers: E2B_03555157, E2B_03550160, E2B_03532951,931919. (ADRs) for Entyvio. Report numbers: 928967, E2B_03541743, E2B_03527627. (ADRs) for Vedolizumab. Report numbers: E2B_03558386,931660, E2B_03581403, E2B_03586230, E2B_03624777, E2B_03635768, E2B_03540996, E2B_03548764. (ADR) for Ixazomib. Report number: E2B_03578204.

Organization: Health Canada

189 page(s)
July 2021

Req # A-2020-001943

Adverse Reaction Reports (AERs) for Mesalazine. Report numbers: E2B_03530029, E2B_03535707, E2B_03522639, E2B_03593963, E2B_03623086, E2B_03596600, E2B_03624831, E2B_03580929, E2B_03567985, E2B_03532944.

Organization: Health Canada

208 page(s)
July 2021

Req # A-2021-000008

Adverse Reaction Reports (AERs). Report numbers: 000916213, E2B_03271142, E2B_03221702, E2B_03386134, E2B_03393048, E2B_03490069, E2B_03498705, E2B_03452314, 000719209, E2B_02036449, E2B_02038328, E2B_02046064, E2B_02063274, E2B_02064174, E2B_02065580, E2B_02084782, E2B_02135694, E2B_02085537, E2B_02167447, E2B_02076619.

Organization: Health Canada

377 page(s)
July 2021

Req # A-2021-000017

Adverse Reaction Reports (AERs) for Statex. Report numbers: E2B_03019592, 000910904. (ADR) for Dexedrine. Report number: 000911336.

Organization: Health Canada

36 page(s)
July 2021

Req # A-2021-000027

Adverse Reaction Reports (AERs). Report numbers: E2B_03533388, E2B_03639203, E2B_03595358, E2B_03534817, E2B_03455974, E2B_03532135, E2B_03534773, E2B_03627942, E2B_03529825, E2B_03529889, E2B_03532071, E2B_03532141, E2B_03543149, E2B_03626691, E2B_03635529, 000684964, 000924456, 000926627, 000926638, 000926699.

Organization: Health Canada

261 page(s)
July 2021

Req # A-2021-000033

Adverse Reaction Reports (AERs). Report numbers: E2B_02175119, E2B_02185249, E2B_02191611, 000719914, E2B_02235927, E2B_02254828, E2B_02359414, E2B_02385312, E2B_02422277, E2B_02445960, E2B_02447810, E2B_02405057, E2B_02515728, 000729387, E2B_02588353, E2B_02704523, E2B_02738003, E2B_02758095, E2B_02773221, E2B_02775410.

Organization: Health Canada

352 page(s)
July 2021
Date modified: